New Veeva Study Builder Agent to Configure Clinical Studies in as Little as One Day
Why now
Thesis: AI tooling for trials, incremental for life-sciences software
Catalyst to watch: Adoption by large pharma sponsors
Main risk: Vendor PR, unproven productivity gains
Why it matters
AI clinical-trial tooling could cut pharma R&D costs, aiding software vendors.
Details
Standards-first agent delivers faster and more consistent EDC and DQS builds PLEASANTON, Calif., Sept. 24, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva Study Builder Agent, a new AI solution that configures Veeva EDC and Veeva DQS (Data Quality System) directly...
Related assets & topics
HealthcareAISources
- prnewswire · 2026-09-24 11:03 UTC
- prnewswire · 2026-09-24 11:03 UTC